- 现金
- 205 元
- 精华
- 1
- 帖子
- 56
- 注册时间
- 2003-2-12
- 最后登录
- 2010-7-20
|
1楼
发表于 2004-2-21 03:11
Epimmune (EPMN) Announces Issuance Of Patent For Epitope-Based Vaccines Targeting Hepatitis B Virus
SAN DIEGO, Feb. 18 /PRNewswire-FirstCall/ -- Epimmune Inc. today announced the issuance of U.S. Patent No. 6,689,363, directed to compositions and methods of using antigen fragments, or epitopes, to induce cellular, or T cell, immune responses for the prevention or treatment of hepatitis B virus (HBV) infection. The issued claims are directed to vaccine compositions made up of epitopes from multiple HBV proteins, identified using Epimmune's proprietary epitope identification technology, designed to provide broader population coverage than prior vaccines.
Dr. Emile Loria, President and Chief Executive Officer of Epimmune said, "This is an important patent for the Company coming shortly after our partner, Genencor International, Inc., announced its anticipated launch of Phase I human clinical trials with a therapeutic hepatitis B vaccine incorporating our epitope technology. As we continue our transition from a research based to a product and clinical development based company, it is an integral part of our strategy to gain additional intellectual property protection for both our own and our partnered programs and products."
|
|